Early clinical development of tazarotene.
Initial clinical investigations on tazarotene, a new acetylenic retinoid, have suggested potential usefulness in the treatment of mild-to-moderate plaque psoriasis. Tazarotene promotes healing of psoriatic lesions by modulating the key pathogenetic factors in this disease. It is not sensitizing, phototoxic, or photoallergenic, but causes moderate dose-related skin irritation. Systemic absorption is minimal and elimination is rapid, providing a low potential for systemic adverse effects. Tazarotene effectively treats mild-to-moderate plaque-type psoriasis, the benefits seem to be sustained after the cessation of therapy, and once-daily treatment is equally effective as more frequent application.
Marks
R
R
Department of Dermatology, University of Wales College of Medicine, Cardiff, U.K.
D002986:Clinical Trials as Topic; D005782:Gels; D006801:Humans; D009539:Nicotinic Acids / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D013723:Teratogens / Q000494:pharmacology*; D012176:Retinoids
D005782:Gels; D009539:Nicotinic Acids; D013723:Teratogens; C086827:tazarotene; D012176:Retinoids